Bristol Myers reports shortage of chemo drug abraxane; Sartorius more than doubles capacity with Michigan expansion
Manufacturing delays have led to a shortage in abraxane, Bristol Myers Squibb says.
The announcement comes on the heels of the FDA shooting down a petition to stall generic version of the drug. Five years after the petition was filed, the FDA rejected it completely in July. The chemotherapy drug brought in more than $1.2 billion for Bristol Myers in 2020.
The shortage affects 100 mg vials of the intravenous lyophilized powder.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.